Standard BioTools Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2025-03-11: Disclosure Non Rule10b51Arr Adopted; Period 2024-10-01..2024-12-31; Value No.
- 2025-03-11: Disclosure Rule10b51Arr Terminated; Period 2024-10-01..2024-12-31; Value No.
- 2025-03-11: Disclosure Non Rule10b51Arr Terminated; Period 2024-10-01..2024-12-31; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2025-03-11 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-11 10-K | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-11 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |